» Articles » PMID: 35966577

Engineered Extracellular Vesicles with High Collagen-binding Affinity Present Superior Retention and Therapeutic Efficacy in Tissue Repair

Overview
Journal Theranostics
Date 2022 Aug 15
PMID 35966577
Authors
Affiliations
Soon will be listed here.
Abstract

Although stem cell-derived extracellular vesicles (EVs) have remarkable therapeutic potential for various diseases, the therapeutic efficacy of EVs is limited due to their degradation and rapid diffusion after administration, hindering their translational applications. Here, we developed a new generation of collagen-binding EVs, by chemically conjugating a collagen-binding peptide SILY to EVs (SILY-EVs), which were designed to bind to collagen in the extracellular matrix (ECM) and form an EV-ECM complex to improve EVs' retention and therapeutic efficacy after transplantation. SILY was conjugated to the surface of mesenchymal stem/stromal cell (MSC)-derived EVs by using click chemistry to construct SILY-EVs. Nanoparticle tracking analysis (NTA), ExoView analysis, cryogenic electron microscopy (cryo-EM) and western-blot analysis were used to characterize the SILY-EVs. Fluorescence imaging (FLI), MTS assay, ELISA and reverse transcription-quantitative polymerase chain reaction (RT-qPCR) were used to evaluate the collagen binding and biological functions of SILY-EVs . In a mouse hind limb ischemia model, the imaging system (IVIS), laser doppler perfusion imaging (LDPI), micro-CT, FLI and RT-qPCR were used to determine the SILY-EV retention, inflammatory response, blood perfusion, gene expression, and tissue regeneration. , the SILY conjugation significantly enhanced EV adhesion to the collagen surface and did not alter the EVs' biological functions. In the mouse hind limb ischemia model, SILY-EVs presented longer retention, suppressed inflammatory responses, and significantly augmented muscle regeneration and vascularization, compared to the unmodified EVs. With the broad distribution of collagen in various tissues and organs, SILY-EVs hold promise to improve the therapeutic efficacy of EV-mediated treatment in a wide range of diseases and disorders. Moreover, SILY-EVs possess the potential to functionalize collagen-based biomaterials and deliver therapeutic agents for regenerative medicine applications.

Citing Articles

Emerging Strategies for Revascularization: Use of Cell-Derived Extracellular Vesicles and Artificial Nanovesicles in Critical Limb Ischemia.

Ravi Mythili V, Rajendran R, Arun R, Loganathbabu V, Reyaz D, Nagarajan A Bioengineering (Basel). 2025; 12(1).

PMID: 39851366 PMC: 11762151. DOI: 10.3390/bioengineering12010092.


Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.

Zheng L, Chang R, Liang B, Wang Y, Zhu Y, Jia Z Cancer Drug Resist. 2025; 7():50.

PMID: 39802949 PMC: 11724354. DOI: 10.20517/cdr.2024.107.


Assessing the conjugation efficiency of surface-modified extracellular vesicles using single nanovesicle analysis technologies.

Goldbloom-Helzner L, Bains H, Loll E, Henson T, Mizenko R, Kumar P Nanoscale. 2024; 16(45):20903-20916.

PMID: 39310954 PMC: 11748815. DOI: 10.1039/d4nr01603c.


Recent Progress in Mesenchymal Stem Cell-Derived Exosomes for Skin Wound Repair.

Xie P, Xue X, Li X Cell Biochem Biophys. 2024; 82(3):1651-1663.

PMID: 38811472 DOI: 10.1007/s12013-024-01328-3.


Approaches to Characterize and Quantify Extracellular Vesicle Surface Conjugation Efficiency.

Goldbloom-Helzner L, Bains H, Wang A Life (Basel). 2024; 14(4).

PMID: 38672781 PMC: 11051464. DOI: 10.3390/life14040511.


References
1.
El Andaloussi S, Mager I, Breakefield X, Wood M . Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5):347-57. DOI: 10.1038/nrd3978. View

2.
Shao J, Zaro J, Shen Y . Advances in Exosome-Based Drug Delivery and Tumor Targeting: From Tissue Distribution to Intracellular Fate. Int J Nanomedicine. 2020; 15:9355-9371. PMC: 7700079. DOI: 10.2147/IJN.S281890. View

3.
Lee S, Choi C, Yoo T . Extracellular vesicles in kidneys and their clinical potential in renal diseases. Kidney Res Clin Pract. 2021; 40(2):194-207. PMC: 8237124. DOI: 10.23876/j.krcp.20.209. View

4.
Hao D, Fan Y, Xiao W, Liu R, Pivetti C, Walimbe T . Rapid endothelialization of small diameter vascular grafts by a bioactive integrin-binding ligand specifically targeting endothelial progenitor cells and endothelial cells. Acta Biomater. 2020; 108:178-193. PMC: 8012081. DOI: 10.1016/j.actbio.2020.03.005. View

5.
Zhang K, Zhao X, Chen X, Wei Y, Du W, Wang Y . Enhanced Therapeutic Effects of Mesenchymal Stem Cell-Derived Exosomes with an Injectable Hydrogel for Hindlimb Ischemia Treatment. ACS Appl Mater Interfaces. 2018; 10(36):30081-30091. DOI: 10.1021/acsami.8b08449. View